COLTENE Holding (CLTN) Fair Value & Analysis
Healthcare · CH · Market cap CHF 316M
Fair value as of: Aug 13, 2026
From 24 valuation models · updated yesterday
Share price −8.0% over the past month.
A solid business, but screening 20% overvalued on our models.
What matters now
- Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (CHF 25.89 to CHF 53.43) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range CHF 42.77 – CHF 113.66 · fair‑value band CHF 25.89 – CHF 53.43 · the CHF 47.75 price screens above the CHF 38.12 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
COLTENE Holding (CLTN) currently trades at CHF 47.75, while our model-based Fair Value estimate is CHF 38.12, implying the stock looks roughly 20.2% overvalued today. The Quality Score stands at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, COLTENE Holding generated revenue of CHF 240M at a net margin of 6.2%. Revenue declined 0.5% year over year. It earns a return on equity of 14.3%. Net debt stands at CHF 26.3M. Fundamentals as of Aug 13, 2026
Our scenario range runs from CHF 25.89 (bear case) to CHF 53.43 (bull case); at CHF 47.75, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 33% below its 52-week high and 13% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at -20%, CLTN screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Multiples (CHF 48.03) versus Asset-Based (CHF 11.27). Highest evidence: Growth DCF (80).
Notify me when CLTN reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 61 · Market factors (momentum, volatility) 44
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
COLTENE Holding AG develops, manufactures, and sells disposables, tools, and equipment for dentists and dental laboratories in Europe, the Middle East, Africa, North America, Latin America, and Asia/Oceania.
Full company description
COLTENE Holding AG develops, manufactures, and sells disposables, tools, and equipment for dentists and dental laboratories in Europe, the Middle East, Africa, North America, Latin America, and Asia/Oceania. The company offers restoration products, including conventional composites, bulk-fill composites, CAD/CAM solutions, core build-ups, bondings, etching gels, temporary materials, luting, curing lights, characterizations, and parapulpal pins; and endodontics products, such as cold sprays, hand files, shaping and retreatment files, endo motors, rinsing and disinfection system, drying, temporary fillings, sealers, guttapercha points, and posts and drills. It also provides prosthetics comprising bite registration, retractions, A-silicones, C-silicones, and accessories; and treatment auxiliaries consist of dental rolls and dispensers, cotton pellets and dispensers, aspirator tips, dental dams, dental dam clamps and accessories, dental scalers, electrosurgery, and occlusion verification products. In addition, the company offers infection control products, which include ultrasonic cleaning solutions, patient bibs, instrument reprocessing, and surface disinfectants; rotary instruments that comprise diamond and carbide burs, polishers, kits, and accessories; and laboratory products, including gingiva masks, lab putty products, model making products, waxes, occlusion control products, and accessories. Further, it provides adhesives, root canal instruments, irrigation solutions, and materials for root canal obturation and sealing; impression materials, wound care and cotton wool products, suction cannulas, rotary instruments, and rubber dams for isolating the treatment area; and thermal disinfectors, washers, cleaning and disinfecting wipes, and autoclaves. The company was formerly known as Medisize Holding AG and changed its name to COLTENE Holding AG in April 2008. COLTENE Holding AG was incorporated in 2005 and is headquartered in Altstätten, Switzerland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
COLTENE Holding reported revenue of CHF 240M in FY2025 versus CHF 279M in FY2021, a compound −3.7%/yr. Reported net income was CHF 14.9M in FY2025, compounding −17.1%/yr from FY2021.
of which total revenue +4.9 pp · buybacks/dilution −4.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
CLTN screens 20% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 201 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $401.27 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €164.40 | €68.55 | -58% |
| Medline Inc MDLN | $35.50 | $30.15 | -15% |
| Becton, Dickinson and Company BDX | $181.41 | $100.46 | -45% |
| Alcon Inc ALC | $73.58 | $39.78 | -46% |
| ResMed Inc RMD | $226.00 | $187.89 | -17% |
| West Pharmaceutical Services, Inc WST | $352.29 | $141.58 | -60% |
| Sartorius Stedim Biotech S.A DIM | €180.30 | €48.88 | -73% |
| Coloplast A/S COLOB | kr 429.70 | kr 382.22 | -11% |
| Gan & Lee Pharmaceuticals., a biopharmaceutical company, 603087 | ¥77.48 | ¥27.22 | -65% |
Compare COLTENE Holding with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is COLTENE Holding (CLTN) overvalued or undervalued?
What is the fair value of CLTN?
What is the quality score of CLTN?
What is the revenue of COLTENE Holding (CLTN)?
What is the net profit margin of CLTN?
Does COLTENE Holding pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track COLTENE Holding and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.